InvestorsHub Logo
Followers 165
Posts 19766
Boards Moderated 2
Alias Born 12/09/2004

Re: Joseph_K post# 455049

Tuesday, 03/26/2024 3:29:29 PM

Tuesday, March 26, 2024 3:29:29 PM

Post# of 462015
The basic situation has not changed significantly.

Anavex is pursuing a completely novel approach to treating AD and other CNS diseases. It is an as yet unproven approach to CNS diseases that is at odds with conventional wisdom.

What has changed is the various trials have strengthened the evidence that Anavex has a valid approach. That is still not an approval for the drug.

Many of the "big boys" will be happy to wait until there is an approval which will validate the Anavex novel approach. Yes they will pay more for shares and they will also incur much less risk. Even with paying more there will still be a lot of money to be made in buying Anavex.

On top of that, the share price has not maintained the $5 SP that is a lower limit for many institutions to buy and hold shares. Why the share price has been so low is a question for each investor to answer for themselves.

It comes down to risk reward balance. The big investors value capital preservation highly and take risks appropriately. Many retail investors are willing to take larger risks in pursuit of larger gains.

I have much of much allocation of high risk money in Anavex. The bulk of my money is in much more conservative investments with a strong bias towards capital preservation.

Nunc est Bibendum

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News